Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
India rejects Gilead’s Hepatitis C drug patent request
Indian health activists move to prevent Gilead’s drug patent
US group seeks to block Gilead drug patent in India
Hepatitis C drug: US group opposes Gilead’s patent request in India
Gilead attempt to secure patent on hepatitis C drug opposed in India
Treatment Advocates Challenge Patent for New Hepatitis C Drug
Gilead Sciences’ Indian patent request for hepatitis C drug sofosbuvir faces opposition
US group seeks block on blockbuster Hep-C drug patent in India
I-MAK challenges Gilead sofosbuvir patent in India
I-MAK Opposes Patent Application on Hepatitis C Drug Sofosbuvir